Discrete Pools of Oligomeric Amyloid-β Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis

American Journal of Pathology

Volumn 188, Issue 3, 2018, Pages 739-756

  Chiang, Angie C A ^a   Fowler, Stephanie W ^a   Reddy, Rohit ^a,b   Pletnikova, Olga ^c   Troncoso, Juan C ^c   Sherman, Mathew A ^d   Lesne, Sylvain E ^d   Jankowsky, Joanna L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b RICE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; DODECYL SULFATE SODIUM;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; LEARNING DISORDER; MALE; MEMORY DISORDER; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SPATIAL LEARNING; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; BRAIN; DISEASE MODEL; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; PATHOLOGY; PHYSIOLOGY; SPATIAL MEMORY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOTOR ACTIVITY; SPATIAL LEARNING; SPATIAL MEMORY;

EID: 85042331342     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2017.11.011     Document Type: Article

References (85)

1. Lesne, S.E., Toxic oligomer species of amyloid-beta in Alzheimer's disease, a timing issue. Swiss Med Wkly, 144, 2014, w14021.
2. Benilova, I., Karran, E., De Strooper, B., The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15 (2012), 349–357.
3. Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71 (2012), 362–381.
4. Blessed, G., Tomlinson, B.E., Roth, M., The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114 (1968), 797–811.
5. Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., Katzman, R., Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30 (1991), 572–580.
6. Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., Hyman, B.T., Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992), 631–639.
7. Berg, L., McKeel, D.W. Jr., Miller, J.P., Baty, J., Morris, J.C., Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 50 (1993), 349–358.
8. McKee, A.C., Kosik, K.S., Kowall, N.W., Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol 30 (1991), 156–165.
9. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, L.M., Vemuri, P., Wiste, H.J., Weigand, S.D., Lesnick, T.G., Pankratz, V.S., Donohue, M.C., Trojanowski, J.Q., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
10. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., Petersen, R.C., Trojanowski, J.Q., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9 (2010), 119–128.
11. Ashe, K.H., Zahs, K.R., Probing the biology of Alzheimer's disease in mice. Neuron 66 (2010), 631–645.
12. Rosenberg, P.B., Wong, D.F., Edell, S.L., Ross, J.S., Joshi, A.D., Brasic, J.R., Zhou, Y., Raymont, V., Kumar, A., Ravert, H.T., Dannals, R.F., Pontecorvo, M.J., Skovronsky, D.M., Lyketsos, C.G., Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. Am J Geriatr Psychiatry 21 (2013), 272–278.
13. Kawas, C.H., Greenia, D.E., Bullain, S.S., Clark, C.M., Pontecorvo, M.J., Joshi, A.D., Corrada, M.M., Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. Alzheimers Dement 9 (2013), 199–203.
14. Kennedy, K.M., Rodrigue, K.M., Devous, M.D. Sr., Hebrank, A.C., Bischof, G.N., Park, D.C., Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. Neuroimage 62 (2012), 1–8.
15. Rodrigue, K.M., Kennedy, K.M., Devous, M.D. Sr., Rieck, J.R., Hebrank, A.C., Diaz-Arrastia, R., Mathews, D., Park, D.C., beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 78 (2012), 387–395.
16. Boyle, P.A., Yu, L., Wilson, R.S., Schneider, J.A., Bennett, D.A., Relation of neuropathology with cognitive decline among older persons without dementia. Front Aging Neurosci, 5, 2013, 50.
17. Lim, Y.Y., Ellis, K.A., Pietrzak, R.H., Ames, D., Darby, D., Harrington, K., Martins, R.N., Masters, C.L., Rowe, C., Savage, G., Szoeke, C., Villemagne, V.L., Maruff, P., Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 79 (2012), 1645–1652.
18. Drzezga, A., Becker, J.A., Van Dijk, K.R., Sreenivasan, A., Talukdar, T., Sullivan, C., Schultz, A.P., Sepulcre, J., Putcha, D., Greve, D., Johnson, K.A., Sperling, R.A., Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 134 (2011), 1635–1646.
19. Chetelat, G., Villemagne, V.L., Pike, K.E., Ellis, K.A., Bourgeat, P., Jones, G., O'Keefe, G.J., Salvado, O., Szoeke, C., Martins, R.N., Ames, D., Masters, C.L., Rowe, C.C., Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 134 (2011), 798–807.
20. Jankowsky, J.L., Slunt, H.H., Gonzales, V., Savonenko, A.V., Wen, J.C., Jenkins, N.A., Copeland, N.G., Younkin, L.H., Lester, H.A., Younkin, S.G., Borchelt, D.R., Persistent amyloidosis following suppression of Aβ production in a transgenic model of Alzheimer's disease. PLoS Med, 2, 2005, e355.
21. Mayford, M., Bach, M.E., Huang, Y.Y., Wang, L., Hawkins, R.D., Kandel, E.R., Control of memory formation through regulated expression of a CaMKII transgene. Science 274 (1996), 1678–1683.
22. Han, H.J., Allen, C.C., Buchovecky, C.M., Yetman, M.J., Born, H.A., Marin, M.A., Rodgers, S.P., Song, B.J., Lu, H.C., Justice, M.J., Probst, F.J., Jankowsky, J.L., Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci 32 (2012), 10574–10586.
23. Rodgers, S.P., Born, H.A., Das, P., Jankowsky, J.L., Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener, 7, 2012, 28.
24. Fowler, S.W., Chiang, A.C., Savjani, R.R., Larson, M.E., Sherman, M.A., Schuler, D.R., Cirrito, J.R., Lesne, S.E., Jankowsky, J.L., Genetic modulation of soluble abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci 34 (2014), 7871–7885.
25. Brody, D.L., Holtzman, D.M., Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp Neurol 197 (2006), 330–340.
26. Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., Vogel, F.S., Hughes, J.P., van Belle, G., Berg, L., The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991), 479–486.
27. Sherman, M.A., Lesne, S.E., Detecting abeta*56 oligomers in brain tissues. Methods Mol Biol 670 (2011), 45–56.
28. Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006), 352–357.
29. King, D.L., Arendash, G.W., Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 75 (2002), 627–642.
30. de Fiebre, N.C., Sumien, N., Forster, M.J., de Fiebre, C.M., Spatial learning and psychomotor performance of C57BL/6 mice: age sensitivity and reliability of individual differences. Age (Dordr) 28 (2006), 235–253.
31. Harburger, L.L., Lambert, T.J., Frick, K.M., Age-dependent effects of environmental enrichment on spatial reference memory in male mice. Behav Brain Res 185 (2007), 43–48.
32. Zhao, X., Rosenke, R., Kronemann, D., Brim, B., Das, S.R., Dunah, A.W., Magnusson, K.R., The effects of aging on N-methyl-D-aspartate receptor subunits in the synaptic membrane and relationships to long-term spatial memory. Neuroscience 162 (2009), 933–945.
33. Lesne, S.E., Sherman, M.A., Grant, M., Kuskowski, M., Schneider, J.A., Bennett, D.A., Ashe, K.H., Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 136 (2013), 1383–1398.
34. Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W., Glabe, C.G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003), 486–489.
35. Willem, M., Tahirovic, S., Busche, M.A., Ovsepian, S.V., Chafai, M., Kootar, S., Hornburg, D., Evans, L.D., Moore, S., Daria, A., Hampel, H., Muller, V., Giudici, C., Nuscher, B., Wenninger-Weinzierl, A., Kremmer, E., Heneka, M.T., Thal, D.R., Giedraitis, V., Lannfelt, L., Muller, U., Livesey, F.J., Meissner, F., Herms, J., Konnerth, A., Marie, H., Haass, C., eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526 (2015), 443–447.
36. Szczepankiewicz, O., Linse, B., Meisl, G., Thulin, E., Frohm, B., Sala Frigerio, C., Colvin, M.T., Jacavone, A.C., Griffin, R.G., Knowles, T., Walsh, D.M., Linse, S., N-terminal extensions retard Abeta42 fibril formation but allow cross-seeding and coaggregation with Abeta42. J Am Chem Soc 137 (2015), 14673–14685.
37. Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A.L., Vigouret, J.M., Paganetti, P., Walsh, D.M., Mathews, P.M., Ghiso, J., Staufenbiel, M., Walker, L.C., Jucker, M., Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313 (2006), 1781–1784.
38. Larson, M., Sherman, M.A., Amar, F., Nuvolone, M., Schneider, J.A., Bennett, D.A., Aguzzi, A., Lesne, S.E., The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer's disease. J Neurosci 32 (2012), 16857–16871a.
39. Jarosz-Griffiths, H.H., Noble, E., Rushworth, J.V., Hooper, N.M., Amyloid-beta receptors: the good, the bad, and the prion protein. J Biol Chem 291 (2016), 3174–3183.
40. Broersen, K., Rousseau, F., Schymkowitz, J., The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?. Alzheimers Res Ther, 2, 2010, 12.
41. Liu, P., Reed, M.N., Kotilinek, L.A., Grant, M.K., Forster, C.L., Qiang, W., Shapiro, S.L., Reichl, J.H., Chiang, A.C., Jankowsky, J.L., Wilmot, C.M., Cleary, J.P., Zahs, K.R., Ashe, K.H., Quaternary structure defines a large class of amyloid-beta oligomers neutralized by sequestration. Cell Rep 11 (2015), 1760–1771.
42. Tomic, J.L., Pensalfini, A., Head, E., Glabe, C.G., Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35 (2009), 352–358.
43. Rasool, S., Albay, R. 3rd, Martinez-Coria, H., Breydo, L., Wu, J., Milton, S., Misra, S., Tran, A., Pensalfini, A., Laferla, F., Kayed, R., Glabe, C.G., Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. Mol Neurodegener, 7, 2012, 37.
44. Rasool, S., Martinez-Coria, H., Wu, J.W., LaFerla, F., Glabe, C.G., Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Abeta deposition and tau pathology in 3xTg-AD mice. J Neurochem 126 (2013), 473–482.
45. Knight, E.M., Kim, S.H., Kottwitz, J.C., Hatami, A., Albay, R., Suzuki, A., Lublin, A., Alberini, C.M., Klein, W.L., Szabo, P., Relkin, N.R., Ehrlich, M., Glabe, C.G., Gandy, S., Steele, J.W., Effective anti-Alzheimer Abeta therapy involves depletion of specific Abeta oligomer subtypes. Neurol Neuroimmunol Neuroinflamm, 3, 2016, e237.
46. Amar, F., Sherman, M.A., Rush, T., Larson, M., Boyle, G., Chang, L., Gotz, J., Buisson, A., Lesne, S.E., The amyloid-beta oligomer Abeta*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. Sci Signal, 10, 2017, eaal2021.
47. Shankar, G.M., Leissring, M.A., Adame, A., Sun, X., Spooner, E., Masliah, E., Selkoe, D.J., Lemere, C.A., Walsh, D.M., Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis 36 (2009), 293–302.
48. Oddo, S., Caccamo, A., Tran, L., Lambert, M.P., Glabe, C.G., Klein, W.L., LaFerla, F.M., Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease: a link between Abeta and tau pathology. J Biol Chem 281 (2006), 1599–1604.
49. Webster, S.J., Bachstetter, A.D., Nelson, P.T., Schmitt, F.A., Van Eldik, L.J., Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet, 5, 2014, 88.
50. Welzel, A.T., Maggio, J.E., Shankar, G.M., Walker, D.E., Ostaszewski, B.L., Li, S., Klyubin, I., Rowan, M.J., Seubert, P., Walsh, D.M., Selkoe, D.J., Secreted amyloid beta-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry 53 (2014), 3908–3921.
51. Klyubin, I., Betts, V., Welzel, A.T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C.A., Cullen, W.K., Peng, Y., Wisniewski, T., Selkoe, D.J., Anwyl, R., Walsh, D.M., Rowan, M.J., Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28 (2008), 4231–4237.
52. Klyubin, I., Walsh, D.M., Lemere, C.A., Cullen, W.K., Shankar, G.M., Betts, V., Spooner, E.T., Jiang, L., Anwyl, R., Selkoe, D.J., Rowan, M.J., Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11 (2005), 556–561.
53. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14 (2008), 837–842.
54. Esparza, T.J., Zhao, H., Cirrito, J.R., Cairns, N.J., Bateman, R.J., Holtzman, D.M., Brody, D.L., Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 73 (2013), 104–119.
55. Upadhaya, A.R., Lungrin, I., Yamaguchi, H., Fandrich, M., Thal, D.R., High-molecular weight Abeta oligomers and protofibrils are the predominant Abeta species in the native soluble protein fraction of the AD brain. J Cell Mol Med 16 (2012), 287–295.
56. Rijal Upadhaya, A., Capetillo-Zarate, E., Kosterin, I., Abramowski, D., Kumar, S., Yamaguchi, H., Walter, J., Fandrich, M., Staufenbiel, M., Thal, D.R., Dispersible amyloid beta-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol Aging 33 (2012), 2641–2660.
57. Klementieva, O., Willen, K., Martinsson, I., Israelsson, B., Engdahl, A., Cladera, J., Uvdal, P., Gouras, G.K., Pre-plaque conformational changes in Alzheimer's disease-linked Abeta and APP. Nat Commun, 8, 2017, 14726.
58. Hayden, E.Y., Conovaloff, J.L., Mason, A., Bitan, G., Teplow, D.B., Preparation of pure populations of covalently stabilized amyloid beta-protein oligomers of specific sizes. Anal Biochem 518 (2017), 78–85.
59. Muller-Schiffmann, A., Andreyeva, A., Horn, A.H., Gottmann, K., Korth, C., Sticht, H., Molecular engineering of a secreted, highly homogeneous, and neurotoxic abeta dimer. ACS Chem Neurosci 2 (2011), 242–248.
60. Born, H.A., Kim, J.Y., Savjani, R.R., Das, P., Dabaghian, Y.A., Guo, Q., Yoo, J.W., Schuler, D.R., Cirrito, J.R., Zheng, H., Golde, T.E., Noebels, J.L., Jankowsky, J.L., Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzheimer's disease. J Neurosci 34 (2014), 3826–3840.
61. Zheng, H., Koo, E.H., Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener, 6, 2011, 27.
62. Bushman, D.M., Kaeser, G.E., Siddoway, B., Westra, J.W., Rivera, R.R., Rehen, S.K., Yung, Y.C., Chun, J., Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains. Elife, 4, 2015, e05116.
63. Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L., et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 14 (2015), 388–405.
64. De Strooper, B., Karran, E., The cellular phase of Alzheimer's disease. Cell 164 (2016), 603–615.
65. Lynch, M.A., Neuroinflammatory changes negatively impact on LTP: a focus on IL-1beta. Brain Res 1621 (2015), 197–204.
66. Williamson, L.L., Bilbo, S.D., Chemokines and the hippocampus: a new perspective on hippocampal plasticity and vulnerability. Brain Behav Immun 30 (2013), 186–194.
67. Yirmiya, R., Goshen, I., Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25 (2011), 181–213.
68. Vom Berg, J., Prokop, S., Miller, K.R., Obst, J., Kalin, R.E., Lopategui-Cabezas, I., Wegner, A., Mair, F., Schipke, C.G., Peters, O., Winter, Y., Becher, B., Heppner, F.L., Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 18 (2012), 1812–1819.
69. Lian, H., Yang, L., Cole, A., Sun, L., Chiang, A.C., Fowler, S.W., Shim, D.J., Rodriguez-Rivera, J., Taglialatela, G., Jankowsky, J.L., Lu, H.C., Zheng, H., NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron 85 (2015), 101–115.
70. Hong, S., Beja-Glasser, V.F., Nfonoyim, B.M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K.M., Shi, Q., Rosenthal, A., Barres, B.A., Lemere, C.A., Selkoe, D.J., Stevens, B., Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352 (2016), 712–716.
71. Rudy, C.C., Hunsberger, H.C., Weitzner, D.S., Reed, M.N., The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease. Aging Dis 6 (2015), 131–148.
72. Vickers, J.C., King, A.E., Woodhouse, A., Kirkcaldie, M.T., Staal, J.A., McCormack, G.H., Blizzard, C.A., Musgrove, R.E., Mitew, S., Liu, Y., Chuckowree, J.A., Bibari, O., Dickson, T.C., Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res Bull 80 (2009), 217–223.
73. Stern, Y., Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 11 (2012), 1006–1012.
74. Rentz, D.M., Locascio, J.J., Becker, J.A., Moran, E.K., Eng, E., Buckner, R.L., Sperling, R.A., Johnson, K.A., Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 67 (2010), 353–364.
75. Vemuri, P., Weigand, S.D., Przybelski, S.A., Knopman, D.S., Smith, G.E., Trojanowski, J.Q., Shaw, L.M., Decarli, C.S., Carmichael, O., Bernstein, M.A., Aisen, P.S., Weiner, M., Petersen, R.C., Jack, C.R. Jr., Alzheimer's Disease Neuroimaging Initiative. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain 134 (2011), 1479–1492.
76. Roe, C.M., Mintun, M.A., D'Angelo, G., Xiong, C., Grant, E.A., Morris, J.C., Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 65 (2008), 1467–1471.
77. Vemuri, P., Lesnick, T.G., Przybelski, S.A., Knopman, D.S., Roberts, R.O., Lowe, V.J., Kantarci, K., Senjem, M.L., Gunter, J.L., Boeve, B.F., Petersen, R.C., Jack, C.R. Jr., Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol 72 (2012), 730–738.
78. Kemppainen, N.M., Aalto, S., Karrasch, M., Nagren, K., Savisto, N., Oikonen, V., Viitanen, M., Parkkola, R., Rinne, J.O., Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 63 (2008), 112–118.
79. Monsell, S.E., Mock, C., Hassenstab, J., Roe, C.M., Cairns, N.J., Morris, J.C., Kukull, W., Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology 83 (2014), 434–440.
80. Lim, Y.Y., Maruff, P., Pietrzak, R.H., Ellis, K.A., Darby, D., Ames, D., Harrington, K., Martins, R.N., Masters, C.L., Szoeke, C., Savage, G., Villemagne, V.L., Rowe, C.C., Abeta and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimers Dement 10 (2014), 743–751.e1.
81. Sperling, R.A., Johnson, K.A., Doraiswamy, P.M., Reiman, E.M., Fleisher, A.S., Sabbagh, M.N., Sadowsky, C.H., Carpenter, A., Davis, M.D., Lu, M., Flitter, M., Joshi, A.D., Clark, C.M., Grundman, M., Mintun, M.A., Skovronsky, D.M., Pontecorvo, M.J., AV45-A05 Study Group. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 34 (2013), 822–831.
82. Pike, K.E., Ellis, K.A., Villemagne, V.L., Good, N., Chetelat, G., Ames, D., Szoeke, C., Laws, S.M., Verdile, G., Martins, R.N., Masters, C.L., Rowe, C.C., Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 49 (2011), 2384–2390.
83. Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., Mathis, C.A., Klunk, W.E., Masters, C.L., Rowe, C.C., Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (2007), 2837–2844.
84. Zhao, R., Fowler, S.W., Chiang, A.C., Ji, D., Jankowsky, J.L., Impairments in experience-dependent scaling and stability of hippocampal place fields limit spatial learning in a mouse model of Alzheimer's disease. Hippocampus 24 (2014), 963–978.
85. Melnikova, T., Fromholt, S., Kim, H., Lee, D., Xu, G., Price, A., Moore, B.D., Golde, T.E., Felsenstein, K.M., Savonenko, A., Borchelt, D.R., Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci 33 (2013), 3765–3779.